Redmile Group, LLC
- SEC CIK
- 0001425738
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 62
- −1 vs. Q3 2024
- Portfolio value
- $1.43B
- −$262.6M (−15.5%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| HOOKHOOKIPA Pharma Inc. | COM | 106,376 | $213.8K | <0.1% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 124,178 | $271.9K | <0.1% | −1,983,037−94.1% | Reduced | History |
| ADAPYAdaptimmune Therapeutics PLC | SPONDS ADR | 715,607 | $385.5K | <0.1% | 00.0% | Unchanged | History |
| KLRSKalaris Therapeutics, Inc. | COM | 1,907,969 | $801.3K | 0.1% | 00.0% | Unchanged | History |
| IVVDInvivyd, Inc. | COM | 3,012,254 | $1.33M | 0.1% | −53,460−1.7% | Reduced | History |
| XERSXeris Biopharma Holdings, Inc. | COM | 451,099 | $1.53M | 0.1% | −595,488−56.9% | Reduced | History |
| Achilles Therapeutics PLC00449L102 | SPONSORED ADS | 1,608,089 | $1.83M | 0.1% | 00.0% | Unchanged | – |
| LVTXLAVA Therapeutics NV | SHS | 2,074,372 | $1.97M | 0.1% | 00.0% | Unchanged | History |
| BOLDBoundless Bio, Inc. | COM | 740,204 | $2.15M | 0.1% | −283,344−27.7% | Reduced | History |
| SLDBSolid Biosciences Inc. | COM NEW | 615,246 | $2.46M | 0.2% | +615,246 | New | History |
| PODDInsulet Corp | Stock | 9,559 | $2.50M | 0.2% | +9,559 | New | History |
| RPTXRepare Therapeutics Inc. | COM | 1,916,089 | $2.51M | 0.2% | −26,466−1.4% | Reduced | History |
| ACIUAC Immune SA | SHS | 1,034,299 | $2.79M | 0.2% | −659,868−38.9% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 346,278 | $3.10M | 0.2% | +35,394+11.4% | Added | History |
| ALLKAllakos Inc. | COM | 3,015,097 | $3.65M | 0.3% | −62,731−2.0% | Reduced | History |
| STXSStereotaxis, Inc. | COM NEW | 1,799,465 | $4.10M | 0.3% | −308,754−14.6% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 92,598 | $4.36M | 0.3% | −4,518−4.7% | Reduced | History |
| ATRAAtara Biotherapeutics, Inc. | COM NEW | 441,701 | $5.88M | 0.4% | −10,569−2.3% | Reduced | History |
| PRMEPrime Medicine, Inc. | COM | 2,074,350 | $6.06M | 0.4% | 00.0% | Unchanged | History |
| PENPenumbra Inc | COM | 25,743 | $6.11M | 0.4% | +11,896+85.9% | Added | History |
| ALXOAlx Oncology Holdings Inc | COM | 3,689,611 | $6.16M | 0.4% | −146,965−3.8% | Reduced | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 1,196,910 | $6.67M | 0.5% | −65,180−5.2% | Reduced | History |
| STTKShattuck Labs, Inc. | COM | 5,539,724 | $6.70M | 0.5% | −75,765−1.3% | Reduced | History |
| VERVVerve Therapeutics, Inc. | COM | 1,318,164 | $7.43M | 0.5% | −65,202−4.7% | Reduced | History |
| ORKAOruka Therapeutics, Inc. | COM | 411,728 | $7.98M | 0.6% | 00.0% | Unchanged | History |
| ARDXArdelyx, Inc. | COM | 1,576,259 | $7.99M | 0.6% | −84,504−5.1% | Reduced | History |
| NUVBNuvation Bio Inc. | COM CL A | 3,031,009 | $8.06M | 0.6% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 552,506 | $8.75M | 0.6% | 00.0% | Unchanged | History |
| ISRGIntuitive Surgical Inc | COM NEW | 16,943 | $8.84M | 0.6% | −9,755−36.5% | Reduced | History |
| BNTXBioNTech SE | SPONSORED ADS | 83,471 | $9.51M | 0.7% | −70,985−46.0% | Reduced | History |
| RAPTRAPT Therapeutics, Inc. | COM | 6,475,317 | $10.2M | 0.7% | +5,970,785+1,183.4% | Added | History |
| SYKStryker Corp | Stock | 30,676 | $11.0M | 0.8% | −2,065−6.3% | Reduced | History |
| CBLLCeribell, Inc. | COM | 435,239 | $11.3M | 0.8% | +435,239 | New | History |
| IMVTImmunovant, Inc. | COM | 571,824 | $14.2M | 1.0% | −70,405−11.0% | Reduced | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 320,149 | $14.7M | 1.0% | +58,346+22.3% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 615,775 | $15.6M | 1.1% | −41,400−6.3% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 619,300 | $15.9M | 1.1% | −61,850−9.1% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 2,399,317 | $16.5M | 1.2% | +500,000+26.3% | Added | History |
| ETNB89bio, Inc. | COM | 2,167,176 | $16.9M | 1.2% | +597,326+38.0% | Added | History |
| IGMSIGM Biosciences, Inc. | COM | 2,952,131 | $18.0M | 1.3% | −120,347−3.9% | Reduced | History |
| FATEFate Therapeutics Inc | COM | 12,872,946 | $21.2M | 1.5% | −296,111−2.2% | Reduced | History |
| ABSIAbsci Corp | COM | 8,253,316 | $21.6M | 1.5% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 3,554,836 | $27.7M | 1.9% | −929,544−20.7% | Reduced | History |
| BSXBoston Scientific Corp | Stock | 312,683 | $27.9M | 1.9% | −18,190−5.5% | Reduced | History |
| NGNENeurogene Inc. | COM | 1,319,763 | $30.2M | 2.1% | +355,416+36.9% | Added | History |
| ADCTADC Therapeutics SA | SHS | 15,666,731 | $31.2M | 2.2% | −2,4860.0% | Reduced | History |
| ANNXAnnexon, Inc. | COM | 6,300,644 | $32.3M | 2.3% | −126,818−2.0% | Reduced | History |
| BHVNBiohaven Ltd. | COM | 904,496 | $33.8M | 2.4% | −129,723−12.5% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 1,235,209 | $34.4M | 2.4% | −152,270−11.0% | Reduced | History |
| RGNXREGENXBIO Inc. | COM | 4,794,780 | $37.1M | 2.6% | −98,122−2.0% | Reduced | History |
| BEAMBeam Therapeutics Inc. | COM | 1,528,567 | $37.9M | 2.6% | −82,446−5.1% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 2,895,478 | $38.1M | 2.7% | −302,013−9.4% | Reduced | History |
| KYMRKymera Therapeutics, Inc. | COM | 1,100,432 | $44.3M | 3.1% | −292,824−21.0% | Reduced | History |
| LIVNLivaNova PLC | SHS | 1,043,539 | $48.3M | 3.4% | +168,500+19.3% | Added | History |
| STOKStoke Therapeutics, Inc. | COM | 4,593,629 | $50.7M | 3.5% | −119,880−2.5% | Reduced | History |
| IMNMImmunome Inc. | COM | 4,828,026 | $51.3M | 3.6% | −61,528−1.3% | Reduced | History |
| REPLReplimune Group, Inc. | COM | 4,905,527 | $59.4M | 4.1% | +124,344+2.6% | Added | History |
| FOLDAmicus Therapeutics, Inc. | COM | 7,054,890 | $66.5M | 4.6% | −1,191,702−14.5% | Reduced | History |
| ZYMEZymeworks Inc. | COM | 4,840,463 | $70.9M | 4.9% | −261,448−5.1% | Reduced | History |
| NRIXNurix Therapeutics, Inc. | COM | 4,192,627 | $79.0M | 5.5% | −88,354−2.1% | Reduced | History |
| KRYSKrystal Biotech, Inc. | COM | 753,175 | $118.0M | 8.2% | −57,070−7.0% | Reduced | History |
| SRRKScholar Rock Holding Corp | COM | 4,549,881 | $196.6M | 13.7% | −688,956−13.2% | Reduced | History |
Sold out since Q3 2024 (4)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| AUGXAugmedix, Inc. | COM | 16,380,327 | $38.5M | 2.3% | History |
| CTLTCatalent, Inc. | COM | 595,570 | $36.1M | 2.1% | History |
| GRTSGritstone bio, Inc. | COM | 4,920,178 | $2.85M | 0.2% | History |
| CABACabaletta Bio, Inc. | COM | 442,826 | $2.09M | 0.1% | History |